Introduction
The utility of adenoviral vectors (Ad) for cancer therapy is limited because they lack specificity for cancer cells. In addition, some tumors lack cellular receptors for adenovirus. Targeting of adenoviral vectors to tumor cells may thus overcome the lack of specificity and improve the transduction efficacy of adenoviral vectors. In addition, this may allow administration of fewer adenoviral particles and thus also decrease vector-related toxicity. Human adenoviruses bind via the carboxy-terminal knob domain of their fiber protein to the recently identified primary cellular receptor CAR (coxsackie/ adenovirus receptor). 1 Following viral attachment, internalization is mediated through interaction of RGD motifs in the penton base with cellular ␣v integrins. Targeting of adenoviruses to tumor cells may be accomplished by replacing the natural receptor binding affinity by a tumor-specific binding domain. Previously, it was shown that an antiknob antibody conjugated to a ligand directed against internalizing cellular receptors can re-route the entry of 4 or integrins. 5 In the present study, we sought to determine if a well-described pan-carcinoma antigen could be utilized to target adenoviral vectors to tumor cells using a bispecific antibody approach.
The pan-carcinoma antigen EpCAM (epithelial cell adhesion molecule) is defined by the mAbs CO17-1A, GA733 6 and 323/A3. 7, 8 The 40-kDa glycoprotein is encoded by the GA733-2 gene. EpCAM is expressed on the cell surface of most carcinomas, including breast, ovary, lung and colon tumors. In normal tissues expression is limited to the baso-lateral cell surface of simple epithelia such as gastrointestinal, lung, breast and thyroid epithelium. The antigen is not shed into the blood, and internalization of antibody bound to tumor cells is relatively slow, with only 50% internalized over a 48 h period. Radiolabeled antibodies against EpCAM have been successfully used to target colorectal cancer in patients thus supporting the usefulness of EpCAM as a tumorselective target molecule. Adjuvant therapy with a MAb directed against EpCAM has been demonstrated to prolong remission and extend survival in patients operated for colorectal cancer. In the present article, we employed a neutralizing antifiber antibody conjugated to an anti-EpCAM antibody to target the adenovirus to tumor cells. The conjugate was complexed with adenoviral vectors carrying reporter genes and was shown to target specifically adenoviral infection to cancer cell lines and primary adenocarcinomas expressing EpCAM. The tumor-specific gene delivery achieved herein should prove of utility in improving Ad-based anti-cancer gene therapy approaches.
Results
Optimization of the anti-EpCAM conjugate To determine the amount of EpCAM targeting conjugate necessary to bind optimally the adenoviral vector to permissive target cells, the conjugate was titrated on AdCMVLuc at a fixed MOI of 100. Gene transfer was measured in terms of luciferase expression in OVCAR-3 cells. EpCAM-targeted gene transfer, expressed in Luciferase activity or expressed as the percentage of cells infected, reached a maximum with a conjugate:virus ratio of 100 ng anti-EpCAM-conjugate per 5.0 × 10 6 p.f.u. (3.3 × 10 8 particles, data not shown). A further increase in the conjugate:virus ratio reduced the magnitude of targeted gene transfer, presumably stemming from competition for EpCAM binding by excess conjugate. At the optimal ratio of conjugate to virus, EpCAM-targeted AdCMVLuc demonstrated a five-to 10-fold enhancement in gene transfer to OVCAR-3 cells, suggesting that on these cells EpCAM-mediated infection is more efficient than CAR-mediated infection.
Specificity of EpCAM targeted AdCMVLuc
To determine if the anti-EpCAM antibody of the conjugate is the basis for the observed enhancement in gene transfer, OVCAR-3 cells were preincubated with the parental anti-EpCAM mAb, 323A3, to occupy EpCAM molecules on the cell surface. Subsequently, an infection was performed with AdCMVLuc targeted to EpCAM at the optimal concentration of anti-EpCAM conjugate. When cells were blocked in this manner a 95% reduction in gene transfer was observed, indicating the EpCAM specificity of the targeted virus ( Figure 1 ). To demonstrate that the gene transfer was independent of the natural receptor for adenovirus, CAR, OVCAR-3 cells were preincubated with excess recombinant fiber knob to block native adenovirus binding to CAR. This incubation had little effect on EpCAM-targeted AdCMVLuc, but greatly reduced gene transfer of native AdCMVLuc, indicating that the binding of the targeted virus is largely CAR-independent. When cells were preincubated with blocking antiEpCAM mAb and excess recombinant knob combined, low levels of luciferase expression were observed for both the native AdCMVLuc and EpCAM-targeted virus.
The observed enhanced gene expression with EpCAMtargeted adenovirus could result from a few transduced cells exhibiting more abundant gene expression or from a greater number of transduced cells. To identify the nature of the enhanced gene expression by EpCAM-targeted adenovirus, the experiment was repeated using an adenoviral vector expressing the LacZ reporter gene. The number of transduced cells was monitored through colorometric staining of individual wells with X-gal. In Figure 2 , it is demonstrated that an increased number of transduced cells was in fact responsible for the observed enhancements in gene transfer in OVCAR-3 cells. The magnitude of the increase in transfection was comparable to that obtained with the AdCMVLuc (compare Figures  1 and 2 ). Thus, EpCAM targeting of the adenoviral vector may allow for enhanced gene delivery to normally refractory cells.
EpCAM targeted AdCMVLuc in cancer cell lines
We wished to determine if the enhanced gene transfer with EpCAM-targeted AdCMVLuc obtained in OVCAR-3 cells could be generalized to cancer cell lines expressing EpCAM. For this purpose we used a series of cancer cell lines of different origin, including colon, ovarian, lung and squamous cell. Cells were infected with AdCMVLuc or EpCAM-targeted AdCMVLuc and luciferase expression was measured. The gene expression after infection with AdCMVLuc showed considerable differences among the different cell lines. The activity was highest in SKOV3 cells which was 10 times higher than that observed in the other extreme, ie GLC cells (Table  1) . When the same cell lines were infected with EpCAMtargeted AdCMVLuc, an enhanced gene expression was found in all cell lines expressing EpCAM. The enhance- Correlation between EpCAM, CAR or integrin expression and infection efficiency of EpCAM targeted AdCMVLuc Native human adenovirus binds to CAR and the internalization of the virus relies on integrins. We sought to determine the correlation between the levels of these proteins on the different tumor cells and their susceptibility for Ad infection. In addition, we measured the EpCAM expression of the cell lines to determine the relation of EpCAM expression and efficacy of EpCAM-targeted Ad infection. Analysis of the expression of CAR, ␣v␤3 and ␣v␤5 expression showed a wide range in the number of these cell surface proteins. No correlation was found between the susceptibility to wild-type Ad infection and CAR or ␣v␤3 expression, whereas the levels of integrin ␣v␤5 correlated well with the susceptibility to adenovirus-mediated gene transfer. The efficiency of EpCAMtargeted Ad gene transfer was clearly dependent on the expression of EpCAM (Table 1) . Cell lines with the highest expression of EPCAM showed the highest increase in gene expression when native AdCMVLuc and targeted AdCMVLuc were compared. Cells with no or low EpCAM expression showed decreased luciferase expression when compared with native AdCMVLuc.
Transduction of primary human colon cancer cells and human liver cells Transduction of primary tumor cells has generally been more difficult than their cell line counterparts. This has been shown, in many instances, to reflect relative scarcity of CAR in primary tumor samples. Thus, achieving CAR independent gene transfer may represent a means, not only for achieving specificity, but also to enhance efficacy. These issues are especially relevant for in vivo delivery, where the phenotype of the tumor and the parenchyma with respect to CAR levels has implications for both efficacy and specificity. To this end, we evaluated targeting of adenoviral vector to colon metastases in the liver. We first determined the efficacy of viral infection in freshly isolated primary human colon cancer cells. The EpCAM targeted gene transfer in primary human colon cancer cells was increased in four out of six tumor specimens obtained from primary colon cancers and comparable to that of native gene transfer in two specimens (Table  2) . Next, we compared the viral infection in colon cancer liver metastases and normal liver cells of the same patient. Gene transfer with the native adenoviral vector was comparable for the liver cells and the primary colon cancer cells. The EpCAM-targeted viral infection in colon cancer liver metastases was slightly increased. In contrast, gene transfer to human liver cells was dramatically reduced by 94-97% with the EpCAM-targeted adenovirus ( Figure 3) . Consequently, gene transfer of EpCAMtargeted adenoviral vector was on average more than 25 times more efficient to cancer cells than to liver cells. Thus, EpCAM targeted adenoviral vectors may be used to direct gene transfer specifically to EpCAM expressing tumor cells sparing normal tissues.
Discussion
In this study we sought to target adenovirus specifically to cancer cells. To accomplish this, we produced a conju- 
Figure 3 Selective infection of human colorectal cancer cells from liver metastases with EpCAM-targeted adenovirus. Human liver cells or human colorectal cancer cells from liver metastases were isolated and infected (50 000 cells per well, MOI = 100) with AdCMVLuc (black bars) or EpCAM-AdCMVLuc (grey bars). The data are expressed as relative light units measured 24 h after infection. Patients are identified with roman numbers. Results are the mean of triplicates.
gate between an adenovirus neutralizing antibody, 1D6.14, and an anti-EpCAM pan-carcinoma antibody, 323A3, to redirect the adenovirus to cancer cells expressing EpCAM. In vitro transduction studies with the EpCAM-targeted adenovirus on cell lines showed that specific gene transfer could be mediated through EpCAM and that this was independent of expression of CAR. In a number of cell lines gene transfer was enhanced when compared with native adenovirus. We have provided evidence that this approach may be used for cancer gene therapy of metastatic colon cancer to the liver by showing higher gene transfer levels in freshly isolated primary human colon cancer cells with EpCAM targeted adenovirus and a dramatic reduction of gene expression in human liver cells.
The development of adenovirus vectors which show tumor-specific gene transfer will enhance their clinical application in the field of human gene therapy for cancer. It may allow administration of fewer adenoviral particles and decrease vector-related toxicity. Several studies have focused on altering adenovirus tropism to direct the virus to cellular receptors other than the native cellular receptor. This concept has been investigated to target adenovirus vectors to specific cell types, including cancer cells, and limit gene transfer in non-target tissues. Wickham et al 5 used a bispecific antibody which recognized a FLAG epitope inserted into the penton base of the adenovirus and ␣v integrins found on a number of cell types. Douglas et al 2 described a method for ablating native adenovirus tropism while conferring new tropism through the use of an antiknob antibody which was conjugated to folic acid for targeting Ad to folate receptor positive cells. This study showed that the tropism modified Ad was able to transduce folate receptor positive cells in vitro efficiently and that this could be achieved in the presence of a folate receptor negative cell line. In addition, the antiknob antibody has been conjugated to the basic fibroblast growth factor for targeting adenovirus to Kaposi's sarcoma cells in vitro. 4 This resulted in an enhanced level of gene transfer when compared with unmodified adenovirus, where less than 1% of the cells were transduced with adenovirus alone compared to Ͼ40% with the conjugate-modified adenovirus.
The above-mentioned studies employed rapidly internalizing cellular receptors as targets for adenoviral entry. Our study shows, for the first time, that a slowly internalizing pan-carcinoma antigen EpCAM can be used for efficient and specific targeting of gene expression through an adenoviral vector. Antibody, bound to EpCAM on the cell surface, is slowly internalized, with only 50% of the antibody present inside the cells after 48 h (Ref . 10 and unpublished results) . Apparently, binding of the EpCAM-targeted adenovirus to the cell surface induces rapid internalization of the virus, possibly through ␣v␤3 or ␣v␤5 integrins because we measured increased luciferase expression in 24 h. If this phenomenon is also true for other cell surface antigens, a variety of tissues may be targeted through bispecific antibodies which recognize the fiber knob and a tissue-specific antigen.
Other investigators have genetically modified the adenovirus to include new binding motivs into the viral capsid 11 or the HI loop. 12 In these studies, the native binding to the CAR receptor was not blocked, and therefore vector tropism was not changed; additional tropism was added in these instances. In addition, in both studies small peptides were used to add new specificity. This will limit the targets that may be used unless new methods are found to include single-chain Fv antibodies as a targeting motive.
The use of EpCAM targeted adenovirus may allow specific in vivo gene transfer to EpCAM-expressing tumors. It should improve current clinical gene therapy approaches for cancer by increasing the therapeutic outcome using the same amount of adenovirus or decreasing the toxicity by using less adenovirus to achieve a similar therapeutic effect. It is this toxicity in several instances that has restricted the dose of virus that could be administered thereby limiting the therapeutic efficacy of conventional gene therapy studies. Even in the treatment of regional disease, where selective transduction of tumor targets should be enhanced, there are still problems of dose-limiting toxicities, particularly hepatotoxicity 13 and low transduction efficiency.
14 The tumor-specific gene delivery described herein should increase the therapeutic index of Ad-based anti-cancer gene therapy approaches.
Materials and methods

Cells, viruses and antibodies
The human cancer cell lines SKOV3, GLC, OVCAR-3, LS174T, HT29, MDA, 22A, 11B, and 293 were obtained from the American Type Culture Collection (Rockville, MD, USA) and were grown in Dulbecco's modified Eagle's medium (DMEM, Life Technologies, Paisley, UK) supplemented with 10% heat-inactivated fetal calf serum (ICN, Costa Mesa, CA, USA), 50 IU/ml penicillin (ICN) and 50 g/ml streptomycin (ICN) in a humidified atmosphere containing 5% CO 2 at 37°C.
Primary human colon cancer cells were obtained from patients undergoing tumor resection. Tumor specimens were excised from surrounding normal tissues and cut into small pieces. Single cell suspensions were prepared by repetitive incubations with collagenase as described. 15 Human liver cells were obtained from tumor-free liver biopsies from patients undergoing a liver resection for metastatic disease. Fragments of liver were incubated with hepatocyte isolation medium (Life Technology, Breda, The Netherlands) for 45 min at 37°C and a single cell suspension was prepared from the detached cells.
AdCMVLuc and AdCMVLacZ
16 are E1/E3-deleted replication deficient Ad5 vectors which express firefly luciferase or ␤-galactosidase, respectively, under the control of the immediate-early cytomegalovirus (CMV) promoter. The viruses were propagated and plaque titered on the permissive line 293 and purified by centrifugation on CsCl gradients by standard techniques. All virus aliquots were stored at −80°C until use.
The neutralizing murine mAb 1D6.14 specific for the receptor binding domain of Ad serotype 5 has been previously described. 2 The mAb 323/A3 (provided by Professor S Warnaar, Centocor, Leiden, The Netherlands) is reactive with the pan-carcinoma antigen EpCAM. 7 Murine mAb RmcB to human coxsackie/adenovirus receptor (a generous gift of Dr Robert Finberg, Dana Farber Cancer Institute) has been described previously. 1 Murine mAbs LM609 to ␣v␤3 and P1F6 to ␣v␤5 integrin were purchased from Chemicon (Temecula, CA, USA) and Gibco BRL (Gaithersburg, MD, USA), respectively.
Conjugation of 1D6.14 and 323/A3-Fab Bispecific conjugates were produced as follows. The FabЈ of 1D6.14 was activated with DTNB at a 1:3 molar ratio in 0.1 m phosphate buffer, pH 8 for 30 min at room temperature. The activated FabЈ (TNB-FabЈ) was purified using size exclusion chromatography (Sephacryl S100 column in 0.1 m phosphate buffer, 0.1 m NaCl and 5 mm EDTA, pH 6) and 0.2 m filtered. 1D6.14 and 323/A3 FabЈ were mixed at a 1:1 mole ratio and incubated overnight at 4°C. The reaction mixture was loaded on to a Sephacryl S200 HR column in PBS, pH 7.4 and fractions containing FabЈ-FabЈ were collected. The fractions were pooled and filtered through a 0.2 m filter, divided into aliquots and stored at −80°C. The material was determined to be 94% pure by size exclusion HPLC. The FabЈ-FabЈ conjugate was analyzed using an anti-knob ELISA and shown to have comparable binding characteristics as the anti-knob FabЈ (data not shown). In addition, final product and intermediates were also characterized by SDS-PAGE under reducing and non-reducing conditions. All materials migrated as expected and the final product was shown to be pure.
Adenoviral vector infection and analysis of gene transfer
We determined the amount of conjugate necessary to target gene transfer optimally with adenovirus to EpCAM positive cells. To this end, the conjugate was titrated on AdCMVLuc (2 × 10 12 part/ml, 3 × 10 10 p.f.u./ml) and gene transfer was measured in terms of luciferase expression in OVCAR-3 cells infected at multiplicity of infection (MOI) of 100. Conjugate and virus were incubated for 30 min at room temperature in a minimal volume. The complexes were added in triplicate to cells plated 24 h earlier in 24-well plates at a density of 50 000 cells per well in DMEM containing 10% FCS and antibiotics (complete medium). Following incubation for 1 h at 37°C, the virus-containing medium was replaced with 0.5 ml complete medium and OVCAR-3 cells were grown an additional 24 h at 37°C. The cells were then lysed and extracts were assayed for luciferase activity using a luciferase assay system (Promega, Madison, WI, USA). In some experiments, the number of cells expressing Luciferase was determined by immunohistochemistry: cells were fixed with cold methanol for 15 min and incubated with an antibody directed against Luciferase (Sigma, St Louis, MO, USA). After washing and incubation with swine anti-rabbit horse-radish-peroxidase antibody (DAKO, Glostrup, Denmark), wells were stained with 3-amino-9-ethylcarbazole. To evaluate the binding specificity of the EpCAM targeted or native AdCMVLuc virus inhibition studies were performed where target cells were preincubated with excess unconjugated 323/A3 mAb or recombinant fiber knob at 100 g/ml for 30 min. The virus-containing medium was replaced with 0.5 ml complete medium and allowed to incubate an additional 24 h at 37°C. The cells were then lysed and extracts were assayed for luciferase activity as described above. The optimal conjugate:virus ratio was used in all subsequent experiments with other cell lines, primary tumor or liver cells.
To evaluate the number of transfected cells, we also used an AdCMVLacZ virus (1.4 × 10 12 part/ml, 4 × 10 10 p.f.u./ml) to infect cells at the conditions which were found to be optimal for the AdCMVLuc virus. At 24 h after infection, the cells were fixed and stained with Xgal using a LacZ assay system (Boehringer Mannheim, Almere, The Netherlands).
Phenotypic analysis
To determine if the infection by virus or targeted virus was dependent on the level of expression of EpCAM, CAR and the integrins ␣v␤3 and ␣v␤5, phenotypic analysis of the various cancer cell lines used in this study was performed. Cells were stained using the MoAbs at 10 g/ml in PBS for 1 h at 0°C. After washing and incubation with a FITC-conjugated rabbit-anti-mouse Ig antibody (DAKO) the samples were washed and analyzed on a FACScan using CellQuest analysis software (Becton Dickinson).
